Kristen Dickert
Family · Fairfax, VANPI 1477949758
Payments from drug & device makers
Across 86 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$318
- Novo Nordisk$237
- Lilly USA, LLC$220
- Boehringer Ingelheim$101
- Takeda Pharmaceuticals U.S.A., Inc.$96
- Pfizer$83
- plus $536 from 19 others
What the payments were for
- Food & beverage$1,592100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $318 |
| Novo Nordisk | 16 | $237 |
| Lilly USA, LLC | 12 | $220 |
| Boehringer Ingelheim | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $96 |
| Pfizer | 3 | $83 |
| Abbott | 3 | $71 |
| Acella Pharmaceuticals, LLC | 3 | $60 |
| AstraZeneca | 3 | $59 |
| Medtronic | 2 | $45 |
| Exact Sciences | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| PBG Puerto Rico LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $12 |
How this compares
$1,592 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $44,253 |
| MounjaroTirzepatide | 18 | $19,759 |
| TrulicityDulaglutide | 30 | $16,057 |
| EntrestoSacubitril/Valsartan | 19 | $13,043 |
| MyrbetriqMirabegron | 25 | $12,007 |
| Nurtec OdtRimegepant Sulfate | 15 | $10,565 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $7,731 |
| JardianceEmpagliflozin | 11 | $6,902 |
| Atorvastatin Calcium | 151 | $2,079 |
| Levothyroxine Sodium | 152 | $1,983 |
| Pantoprazole Sodium | 114 | $1,699 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $1,652 |
| Tamsulosin Hcl | 69 | $1,572 |
| Memantine Hcl | 33 | $1,506 |
| Midodrine Hcl | 15 | $1,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $83 | $54,81894 claims |
| Lilly USA, LLCMounjaro, Trulicity | $220 | $35,81648 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $12,00725 claims |
| Boehringer IngelheimJardiance | $101 | $6,90211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.
Other family in Fairfax
- Meagan AdamsonFairfax$34K
- Christine HelouFairfax$28K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.